On the other hand, NOS2 inhibition could induce GSCs to release EVs with a modified cargo that is able to alter and manipulate the tumor inflammatory microenvironment in order to make it less advantageous to tumor growth and invasiveness. Here, NOS2 is linked to neoplasm.